Full-Time

Artificial Intelligence / Machine Learning Engineer

Vaccine Research

Posted on 5/9/2026

Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$106k - $176.6k/yr

No H1B Sponsorship

New City, NY, USA

Hybrid

Hybrid role; on-site about 2.5 days per week, within commuting distance.

Category
AI & Machine Learning (1)
Required Skills
MLOps
Python
Tensorflow
Pytorch
Machine Learning
Requirements
  • PhD in Computer Science, Machine Learning, Computational Biology, Software Engineering, Artificial Intelligence, or a related discipline OR Master’s degree in Computer Science, Machine Learning, Computational Biology, Software Engineering, Artificial Intelligence, or a related discipline and a minimum of 2 years of applied AI/ML experience in a Vaccines R&D, Life Sciences or other related discovery focused environment
  • Working knowledge of vaccine R&D workflows, including target identification, antigen design and optimization, translational science, clinical development, or portfolio analytics
  • Experience operating fluently across disciplines - molecular biology, systems immunology, pharmacology, and statistics – grounding AI models in biological and clinical reality
  • Demonstrated expertise in foundation model, predictive modeling, generative AI, and ML system design
  • Strong programming skills in Python and modern ML frameworks (e.g., PyTorch, TensorFlow), with experience scaling models in cloud and/or HPC environments
  • Experience collaborating with Experimental Scientists, Clinicians, and cross-functional partners
  • Clear scientific communicator with intellectual curiosity and a mission-driven mindset focused on improving patient outcomes
Responsibilities
  • Shape scientific strategy with AI: design, develop, and deploy AI systems directly influencing vaccine discovery and development decisions, informing antigen selection, experimental prioritization, translational strategies, and clinical study design
  • Serve as scientific thought partner to vaccine R&D leaders, helping integrate AI-driven insights into program-level and portfolio-level strategy
  • Own foundational and predictive modeling end-to-end: Lead AI initiatives spanning antigen discovery and optimization, experimental design, translational modeling, clinical trial simulation, patient stratification, and operational forecasting
  • Take models from concept through validation, deployment, and measurable scientific impact
  • Advance generative AI for vaccine design: Apply state-of-the-art generative and foundation models to protein and antigen engineering; rapidly prototype, rigorously evaluate, and responsibly deploy AI methods in high-stakes scientific contexts
  • Engineer robust, scalable AI systems: Architect reliable ML pipelines using modern MLOps practices across cloud and HPC environments, with strong attention to reproducibility, governance, and scientific credibility
  • Standardize and automate the ML lifecycle, enabling long-term sustainability, compliance, and auditability
  • Decode high-dimensional biology and stay at the scientific frontier: Integrate multimodal datasets – including omics, immunological data, clinical and real-world evidence, and scientific literature - to uncover biological insight and guide experimental and clinical decision-making
  • Continuously assess emerging AI methods and technologies, translating cutting-edge advances into practical, defensible applications for vaccine research
  • Elevate AI fluency across the organization and represent Pfizer science externally: Mentor Scientists and Engineers, foster scientific curiosity, and help build a culture where AI-enabled experimentation and learning are embedded in daily R&D practice
  • Publish, present, and engage with the broader AI, immunology, infectious disease, and vaccine/life-sciences community at leading scientific conferences and forums

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, offsetting COVID product declines.
  • VYNDAMAX patent extension to 2031 stabilizes 75% market share cardiology revenue.
  • ELREXFIO Phase 3 data positions multiple myeloma drug against J&J, BMS competitors.

What critics are saying

  • Eliquis patent expiration 2026-2027 eliminates $1.5B revenue via generic competition.
  • Ibrance patent cliff 2027 erodes $5B+ annual oncology revenue with no successor.
  • COVID product sales collapsed from $56.7B 2022 to $5B projected 2026.

What makes Pfizer unique

  • Seagen acquisition doubled oncology pipeline to 60 programs with proprietary ADC technology.
  • VEPPANU first FDA-approved oral PROTAC therapy for endocrine-resistant breast cancer.
  • HYMPAVZI EU approval targets 20% hemophilia A patients with inhibitors, 93% bleeding reduction.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pfizer who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.